Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Transfusion ; 53(1): 156-66, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22624624

RESUMEN

BACKGROUND: Standardization of platelet-derived microparticle (PMP) enumeration by flow cytometry (FCM) is limited due to its intrinsic characteristics. Because of high clinical relevance of microparticle (MP) detection, standardization of MP assays is required. STUDY DESIGN AND METHODS: This prospective paired study analyzed 31 healthy blood donors (18 male, 13 female) and compared pre- and postdonation results of donors with results of plateletpheresis products by three different methods. PMP counts were analyzed by FCM using calibrated beads of defined diameter and annexin V-fluorescein isothiocyanate and CD41-phycoerythrin staining. MP activity was tested by prothrombinase assay (enzyme-linked immunosorbent assay [ELISA]) and a procoagulant phospholipid-dependent clotting time assay (STA-Procoag-PPL, Diagnostica Stago S.A.S.). RESULTS: PMP concentration was more than threefold higher in single-platelet units (SPUs) and resulted in higher PMP yields in SPUs compared to double-platelet units (DPUs). The ELISA and the procoagulant clotting assay also revealed a significant higher MP activity in SPUs compared to DPUs. The results of the procoagulation clotting assay correlated inversely with PMP counts obtained by FCM (r = -0.685, p < 0.001) and with the MP activity measured by ELISA (r = -0.641, p < 0.001). CONCLUSION: Three different methods for MP detection showed good correlations of results, albeit the basis for MP analysis was different. Even if FCM is considered the "gold standard" of MP detection there are still technical limitations concerning detection of small MP. The procoagulant STA-Procoag-PPL assay and the prothrombinase ELISA assay could be useful additional MP tests. Regarding the interpretation of quantitative results of MPs, preanalytical conditions must be optimized and standardized.


Asunto(s)
Plaquetas/metabolismo , Plaquetoferesis , Adulto , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Humanos , Masculino , Ficoeritrina , Glicoproteína IIb de Membrana Plaquetaria/metabolismo , Estudios Prospectivos , Adulto Joven
2.
Platelets ; 13(3): 133-40, 2002 May.
Artículo en Inglés | MEDLINE | ID: mdl-12180495

RESUMEN

The platelet integrin alphaIIb beta3 (GPIIb/IIIa) acts as a receptor for fibrinogen, playing a critical role in platelet aggregation. GPIIb/IIIa antagonists, which block the receptor-ligand interaction, have been accused of causing occasional thrombocytopenia, probably via drug-induced platelet activation or immunogenic neoepitopes. We, therefore, analyzed the effects of the GPIIb/IIIa antagonist MK-383 (tirofiban) on platelet activation and GpIIb/IIIa conformation. At a concentration of 10(-7) mol/l, MK-383 completely inhibited fibrinogen binding to in vitro stimulated platelets. Simultaneously, the GPIIb/IIIa expression density increased, similar to that on activated platelets, but no effect on P-selectin expression or the formation of platelet-leukocyte aggregates could be observed, indicating that MK-383 binding did not induce general platelet activation. The GPIIb/IIIa receptor conformation was further analyzed by fluorescence resonance energy transfer analysis between fluorochrome-labeled antibodies against different GpIIb/IIIa epitopes. As a result, MK-383 induced a receptor conformation that differed from the resting as well as the activated receptor as induced by ADP or TRAP-6. This conformational modulation of GPIIb/IIIa presents an interesting mechanism which may be linked to receptor recruitment without inducing general platelet activation.


Asunto(s)
Inhibidores de Agregación Plaquetaria/farmacología , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/química , Tirosina/farmacología , Citometría de Flujo , Transferencia Resonante de Energía de Fluorescencia , Humanos , Activación Plaquetaria/efectos de los fármacos , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/efectos de los fármacos , Conformación Proteica/efectos de los fármacos , Tirofibán , Tirosina/análogos & derivados
3.
Traffic ; 3(4): 268-78, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11929608

RESUMEN

We have investigated whether a raft heterogeneity exists in human monocyte-derived macrophages and fibroblasts and whether these microdomains are modulated by lipid efflux. Triton X-100 (Triton) or Lubrol WX (Lubrol) detergent-resistant membranes from cholesterol-loaded monocytes were associated with the following findings: (i) Lubrol-DRM contained most of the cellular cholesterol and at least 75% of Triton-detergent-resistant membranes. (ii) 'Lubrol rafts', defined by their solubility in Triton but insolubility in Lubrol, were enriched in unsaturated phosphatidylcholine and showed a lower cholesterol to choline-phospholipid ratio compared to Triton rafts. (iii) CD14 and CD55 were recovered in Triton- and Lubrol-detergent-resistant membranes, whereas CD11b was found exclusively in Triton DRM. ABCA1 implicated in apo AI-mediated lipid efflux and CDC42 were partially localized in Lubrol- but not in Triton-detergent-resistant membranes. (iv) Apo AI preferentially depleted cholesterol and choline-phospholipids from Lubrol rafts, whereas HDL3 additionally decreased the cholesterol content of Triton rafts. In fibroblasts, neither ABCA1 nor CDC42 was found in Lubrol rafts, and both apo AI and HDL3 reduced the lipid content in Lubrol- as well as in Triton-detergent-resistant membranes. In summary, we provide evidence for the existence of compositionally distinct membrane microdomains in human cells and their modulation by apo AI/ABCA1-dependent and HDL3-mediated lipid efflux.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/metabolismo , Apolipoproteína A-I/metabolismo , Colesterol/metabolismo , Metabolismo de los Lípidos , Lipoproteínas HDL/metabolismo , Transportador 1 de Casete de Unión a ATP , Transporte Biológico , Antígenos CD55/biosíntesis , Membrana Celular/metabolismo , Células Cultivadas , Colina/metabolismo , Detergentes/farmacología , Electroforesis en Gel de Poliacrilamida , Fibroblastos/metabolismo , Humanos , Immunoblotting , Receptores de Lipopolisacáridos/biosíntesis , Macrófagos/metabolismo , Microdominios de Membrana/metabolismo , Microscopía Fluorescente , Microvellosidades/metabolismo , Monocitos/metabolismo , Octoxinol/farmacología , Péptidos/química , Pruebas de Precipitina , Estructura Terciaria de Proteína , Proteína de Unión al GTP cdc42/biosíntesis
4.
Eur J Immunol ; 33(5): 1399-408, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12731067

RESUMEN

Recently, we described an 80-kDa lipopolysaccharide (LPS)-binding membrane protein to be identical to CD55 [decay accelerating factor (DAF)]. Here, we demonstrate that CD55 is able to contribute to lipopolysaccharide (LPS) signaling. Transfection of Chinese hamster ovary (CHO) cells with human CD55 resulted in a translocation of NF-kappa B after stimulation with LPS as well as with free lipid A. In addition, interaction of lipid A and CD55 was shown by co-immuno-precipitation of these molecules from CHO-CD55 cells after incubation with lipid A and anti-lipid A monoclonal antibody, as well as by fluorescence resonance energy transfer (FRET) analysis in human monocytes. The comparison of LPS-induced signaling pathways in CHO-CD55 and CHO-CD14 cells revealed that p38, JNK and ERK MAP kinases are activated upon LPS stimulation in both cell lines, and that the activation by LPS can be blocked at the level of Toll-like receptor 4. Finally, through FRET analysis we could demonstrate LPS-induced clustering of CD55 and CD11/CD18 in human monocytes. Our results imply a new functional role of CD55 as a member of a multimeric LPS receptor complex.


Asunto(s)
Antígenos CD55/fisiología , Receptores de Lipopolisacáridos/fisiología , Lipopolisacáridos/farmacología , Transducción de Señal , Animales , Células CHO , Cricetinae , Activación Enzimática , Humanos , Lípido A/metabolismo , Lípido A/farmacología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , FN-kappa B/metabolismo , Pruebas de Precipitina , Transporte de Proteínas , Transfección
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA